In accordance with the Nomination Committee Charter adopted at the Annual General Meeting 2026, the members who, together with the Chair of the Board, constitute the Nomination Committee in preparation of the Annual General Meeting 2027 have been appointed.

The Nomination Committee consists of:
Niels Jacobsen, appointed by William Demant Invest A/S
Patrik Tigerschiöld, appointed by Bure Equity AB
Rikke Reinemo, appointed by Ferd AS
Jón Sigurdsson, Chairman of the Board

The Annual General Meeting of Vitrolife AB will be held in Gothenburg on 4 May 2027.

Shareholders who wish to submit proposals to the Nomination Committee can do so in writing to investors@vitrolife.com or to Vitrolife AB (publ), Attn:Nomination Committee, P. O. Box 9080, SE-400 92 Gothenburg, Sweden.

Gothenburg, 3 November, 2026
VITROLIFE AB (publ)

Contact:
Cecilia Möllerstrandh
Investor Relations
investors@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About Us
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden.
Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

Attachments
Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2027

Läs mer på MFN